The Inhibitory Effect of Aspirin on Fibrinolysis Is Reversed by Iloprost, a Prostacyclin Analogue

Summary

The reduced fibrinolytic response after aspirin intake may be due to prevention of prostacyclin production. The effect of iloprost (a stable prostacyclin analogue) was tested on the fibrinolytic activity (euglobulin lysis area on fibrin plate [E.L.A.], t-PA antigen, PAI activity and PAI-1 antigen) of plasma drawn after venous stasis test from six healthy male volunteers, who each received all the following treatments according to a single-blind randomized cross-over design: placebo, iloprost, aspirin + placebo, aspirin + iloprost. The mean E. L. A. value after venous occlusion was significantly higher than the basal level after every treatment, but aspirin. Within each treatment group the t-PA antigen levels in response to venous stasis were significantly higher than the basal ones. PAI-1 antigen levels did not change significantly before and after venous stasis either within or among the treatment groups. These data are consistent with the hypothesis that the mechanism related to aspirin’s effect on fibrinolysis is mediated by suppression of vessel wall prostacyclin production. Aspirin’s inhibitory effect on fibrinolysis was in fact prevented by replacing endogenous prostacyclin with iloprost. Iloprost enhances fibrinolytic activity reduced by aspirin, but not by promoting t-PA release or by inhibiting release of the specific inhibitor, PAI-1.

Keywords

Aspirin - Fibrinolytic activity - Prostacyclin analogues

• References

• 1 Levin RI, Harpel PC, Weil D, Chang TS, Rifkin DB. Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 1984; 74: 571-580
• 2 De Gaetano G, Carriero MM, Cerletti C, Mussoni L. Low dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochem Pharmacol 1986; 35: 3147-3150
• 3 Keber I, Jereb M, Keber D. Aspirin decreases fibrinolytic potential during venous occlusion, but not during acute physical activity. Thromb Res 1987; 46: 205-212
• 4 Bounameaux H, Gresele P, Hanss M, De Cock F, Vermylen J, Collen DAspirin. indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thromb Res 1985; 40: 161-170
• 5 Korninger C, Kirchheimer J, Christ G, Schwaiger N, Binder BR. Failure of aspirin to inhibit t-PA release after venous occlusion. Thromb Haemostas 1985; 54: 175 (Abstr 01032)
• 6 Hammouda MW, Moroz LA. Aspirin and venous occlusion: Effects on blood fibrinolytic activity and tissue-type plasminogen activator levels. Thromb Res 1986; 42: 73-82
• 7 Conkie JA, McCall F, Walker ID, Davidson JF. The effect of aspirin on fibrinolysis. In: Eighth Int. Congress on Fibrinolysis. Vienna: 1988. Fibrinolysis special issue (Abstr 202)
• 8 Bertelé V, Mussoni L, Del Rosso G, Pintucci G, Carriero MM, Merati MG, Libretti A, De Gaetano G. Defective fibrinolytic response in atherosclerotic patients. Effect of iloprost and its possible mechanism of action. Thromb Haemostas 1988; 60: 141-144
• 9 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 10 Kruithof EK O, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
• 11 Winer BJ. Statistical Principles in Experimental Design (2nd ed). MacGraw-Hill; London: 1971
• 12 Utsunomiya T, Krausz MM, Valeri CR, Shepro D, Hechtman HB. Treatment of pulmonary embolism with prostacyclin. Surgery 1980; 88: 25-30
• 13 Schneider J. Stimulation of the plasma fibrinolytic activity in rats by the prostacyclin analogue CG 4203. Thromb Res 1987; 48: 233-244
• 14 Dembińska-Kieć A, Kostka-Trąbka E, Gryglewski RJ. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemostas 1982; 47: 190
• 15 Szczeklik A, Kopec M, Sladek K, Musial J, Chmielewska J, Teisseyre E, Dudek-Wojciechowska G, Palester-Chlebowczyk M. Prostacyclin and the fibrinolytic system in ischemic vascular disease. Thromb Res 1983; 29: 655-660
• 16 Musial J, Wilczynska M, Sladek K, Cierniewski CC, Nizankowski R, Szczeklik A. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 1986; 31: 61-70
• 17 FitzGerald GA, Smith B, Pedersen AA, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
• 18 D’Angelo V, Villa S, Mysliwiec M, Donati MM, De Gaetano G. Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemostas 1978; 39: 535-536
• 19 Mysliwiec M, Villa S, Kornblihtt L, De Gaetano G, Donati MB. Decreased plasminogen activator but normal prostacyclin activity in rat veins during development of experimental thrombosis. Thromb Res 1980; 18: 159-165
• 20 Keber D. Mechanism of tissue plasminogen: Activator release during venous occlusion. Fibrinolysis 1988; 2 Suppl (Suppl. 02) 96-103